Agreement - May 8, 2017
NNIT, Novo Nordisk renew agreement
NNIT has signed an extension of its infrastructure outsourcing agreement with Novo Nordisk. The estimated total value of the agreement amounts to approximately DKK 1bn and covers global services, including support and maintenance of Novo Nordisk’s corporate IT infrastructure. The agreement covers Novo Nordisk’s global IT infrastructure and further supports the pharmaceutical company’s cloud strategy […]
Profiles in Pharma - March 8, 2017
“We have to embrace the new era of diabetes care”
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development strategy, the new era of diabetes care and his 25 year-long passion for his job. The changing diabetes market, with increasing competition and high prices for diabetes products in the US, has made the world’s […]
Agreement - January 31, 2017
Novo Nordisk invests in new research center
University of Oxford and Novo Nordisk announces a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes. As part of the collaboration, Novo Nordisk is also investing in a new research centre on […]
Collaboration - January 30, 2017
Novo Nordisk and Glooko partner
Novo Nordisk and Glooko announces that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk’s knowledge of diabetes with Glooko’s digital platform and data analytics expertise. Building on Glooko’s mobile and web platforms, the companies aim to deliver personalised, […]
Logistics - January 18, 2017
Reaching out
Two global life science firms share some of their projects and logistical solutions to deliver healthcare to parts of the world where it is needed the most. Cardiovascular disease is currently the third leading killer in Africa. Hypertension, one of the main risk factors for cardiovascular disease, is estimated to affect nearly half of adults […]
Clinical Trials - December 6, 2016
New phase 3b results from Novo Nordisk
Novo Nordisk has announced new phase 3b trial (DUAL VII) results with Xultophy (IDegLira). Xultophy is a once-daily, single injection fixed combination of a long-acting basal insulin (insulin degludec) and a glucagon-like peptide-1 (GLP-1) receptor agonist (liraglutide).1 The open-label trial investigated the efficacy and safety of Xultophy compared with insulin glargine U100 in combination with […]
